These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9610980)

  • 1. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
    Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
    Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.
    Infante AF; Elmes AT; Gimbar RP; Messmer SE; Neeb C; Jarrett JB
    Int J Drug Policy; 2024 Feb; 124():104323. PubMed ID: 38232438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo characterization of the opioid antagonist nalmefene in mice.
    Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
    Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalmefene hydrochloride.
    Chumpa A
    Pediatr Emerg Care; 1999 Apr; 15(2):141-3. PubMed ID: 10220088
    [No Abstract]   [Full Text] [Related]  

  • 7. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nalmefene in the treatment of interstitial cystitis.
    Stone NN
    Urol Clin North Am; 1994 Feb; 21(1):101-6. PubMed ID: 8284832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.
    Stolbach AI; Mazer-Amirshahi ME; Nelson LS; Cole JB
    Clin Toxicol (Phila); 2023 Nov; 61(11):952-955. PubMed ID: 38039052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
    Kaplan JL; Marx JA
    Ann Emerg Med; 1993 Feb; 22(2):187-90. PubMed ID: 8427429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
    Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
    Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
    Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
    Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
    Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nalmefene. JF 1, nalmetrene, NIH 10365, ORF 11676, Arthrene, Cervene, Incystene, Revex.
    Drugs R D; 1999 Jan; 1(1):32-3. PubMed ID: 10565979
    [No Abstract]   [Full Text] [Related]  

  • 16. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene--a long-acting injectable opioid antagonist.
    Med Lett Drugs Ther; 1995 Oct; 37(960):97-8. PubMed ID: 7565300
    [No Abstract]   [Full Text] [Related]  

  • 18. Opioid Withdrawal Precipitated by Long-Acting Antagonists.
    Kunzler NM; Wightman RS; Nelson LS
    J Emerg Med; 2020 Feb; 58(2):245-253. PubMed ID: 32005608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.
    Joshi GP; Duffy L; Chehade J; Wesevich J; Gajraj N; Johnson ER
    Anesthesiology; 1999 Apr; 90(4):1007-11. PubMed ID: 10201671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
    Franchitto N; Jullian B; Salles J; Pelissier F; Rolland B
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):669-677. PubMed ID: 28343423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.